Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

Publications

Ribeiro R, Teixeira A, Lopes T, Cruz C

A Case of Acute Eosinophilic Pneumonia Associated With Non-steroidal Anti-inflammatory Drugs.

Cureus. 2024;16(1):e52159

Krabansky F, Azzouz B, Biya J, Abou Taam M, Morel A, Trenque T

Eosinophilic pneumonia induced by non-steroidal anti-inflammatory drugs: An underestimated risk.

Therapie. 2018;73(6):473-482

Berger D, Pichler W, Savic S, Schoenenberger R, Borer H

[Fever, pneumonia and eosinophilia].

Praxis. 2007;96(40):1543-7

Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC

Pulmonary drug toxicity: radiologic and pathologic manifestations.

Radiographics : a review publication of the Radiological Society of North America, Inc. 2000;20(5):1245-59

Pfitzenmeyer P, Meier M, Zuck P, Peiffer G, Masson P, Turcu A, Piard F, Camus P

Piroxicam induced pulmonary infiltrates and eosinophilia.

The Journal of rheumatology. 1994;21(8):1573-7

Goodwin SD, Glenny RW

Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports.

Archives of internal medicine. 1992;152(7):1521-4